In contrast, studies using long-term estrogen-deprived breast cancer cells have shown that AI resistance is controlled by several signaling pathways including the P13K/AKT pathway, the insulin-like growth factor receptor (IGF-1R) pathway, and the HER2 pathway [39-41]. Here, ERBB2 is linked to breast carcinoma.